Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362531/
https://www.ncbi.nlm.nih.gov/pubmed/37390313
http://dx.doi.org/10.1182/bloodadvances.2023010270
_version_ 1785076443299971072
collection PubMed
description
format Online
Article
Text
id pubmed-10362531
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-103625312023-07-23 Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908. Blood Adv Erratum The American Society of Hematology 2023-07-03 /pmc/articles/PMC10362531/ /pubmed/37390313 http://dx.doi.org/10.1182/bloodadvances.2023010270 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Erratum
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title_full Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title_fullStr Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title_full_unstemmed Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title_short Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
title_sort ilich a, gernsheimer tb, triulzi dj, et al. absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. blood adv. 2023;7(6):900-908.
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362531/
https://www.ncbi.nlm.nih.gov/pubmed/37390313
http://dx.doi.org/10.1182/bloodadvances.2023010270

Ejemplares similares